There is no age limit for methadone: A retrospective cohort study

Substance Abuse: Treatment, Prevention, and Policy

Volumn 6, Issue 1, 2011, Pages

  Dürsteler MacFarland, Kenneth M ^a,b   Vogel, Marc ^a   Wiesbeck, Gerhard A ^a   Petitjean, Sylvie A ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL OF PSYCHIATRY   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

METHADONE; NARCOTIC AGENT;

ADULT; AGE; ARTICLE; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; MALE; MIDDLE AGED; OPIATE SUBSTITUTION TREATMENT; RETROSPECTIVE STUDY; SOCIOECONOMICS; STATISTICS; SWITZERLAND;

ADULT; AGE FACTORS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; METHADONE; MIDDLE AGED; NARCOTICS; OPIATE SUBSTITUTION TREATMENT; RETROSPECTIVE STUDIES; SOCIOECONOMIC FACTORS; SWITZERLAND;

EID: 79955954302     PISSN: None     EISSN: 1747597X     Source Type: Journal    
DOI: 10.1186/1747-597X-6-9     Document Type: Article

References (72)

1. Nordt C, Stohler R. Incidence of heroin use in Zurich, Switzerland: a treatment case register analysis. Lancet 2006, 367:1830-1834. 10.1016/S0140-6736(06)68804-1, 16753485.
2. European Monitoring Centre for Drugs and Drug Addiction Annual report 2010: the state of the drugs problem in Europe Luxembourg: Publications Office of the European Union; 2010, European Monitoring Centre for Drugs and Drug Addiction.
3. Hser YI, Hoffman V, Grella CE, Anglin MD. A 33-year follow-up of narcotics addicts. Arch Gen Psychiatry 2001, 58:503-508. 10.1001/archpsyc.58.5.503, 11343531.
4. National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction Effective Medical Treatment of Opiate Addiction. JAMA 1998, 280:1936-1943. 10.1001/jama.280.22.1936, 9851480, National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction.
5. Ward J, Hall W, Mattick RP. Role of maintenance treatment in opioid dependence. Lancet 1999, 353:221-226. 10.1016/S0140-6736(98)05356-2, 9923893.
6. Eder H, Jagsch R, Kraigher D, Primorac A, Ebner N, Fischer G. Comparative study of the effectiveness of slow-release morphine and methadone for opioid maintenance therapy. Addiction 2005, 100:1101-1109. 10.1111/j.1360-0443.2005.001128.x, 16042640.
7. Kreek MJ, Vocci FJ. History and current status of opioid maintenance treatments: blending conference session. J Subst Abuse Treat 2002, 23:93-105. 10.1016/S0740-5472(02)00259-3, 12220607.
8. Strain EC, Stitzer ML. The Treatment of Opioid Dependence. 2006, Baltimore: Johns Hopkins University Press.
9. Magura S, Rosenblum A. Leaving methadone treatment: lessons learned, lessons forgotten, lessons ignored. Mt Sinai J Med 2001, 68:62-74.
10. Van den Brink W, Haasen C. Evidenced-based treatment of opioid-dependent patients. Can J Psychiatry 2006, 51:635-646.
11. Dole VP, Nyswander ME. A medical treatment for diacetylmorphine (heroin) addiction. Journal of the American Medical Association 1965, 193:646-650.
12. Donny EC, Walsh SL, Bigelow GE, Eissenberg T, Stitzer ML. High-dose methadone produces superior opioid blockade and comparable withdrawal suppression to lower doses in opioid-dependent humans. Psychopharmacology (Berl) 2002, 161:202-212.
13. Ball JC, Ross A. The effectiveness of methadone maintenance treatment: patients, programs, services, and outcome 1991, New York: Springer Verlag.
14. Marsch LA. The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: a meta-analysis. Addiction 1998, 93:515-532. 10.1046/j.1360-0443.1998.9345157.x, 9684390.
15. Zaric GS, Barnett PG, Brandeau ML. HIV transmission and the cost-effectiveness of methadone maintenance. Am J Public Health 2000, 90:1100-1111. 10.2105/AJPH.90.7.1100, 1446290, 10897189.
16. Leshner AI. Science-based views of drug addiction and its treatment. JAMA 1999, 282:1314-1316. 10.1001/jama.282.14.1314, 10527162.
17. McLellan AT, Arndt IO, Metzger DS, Woody GE, O'Brien CP. The effects of psychosocial services in substance abuse treatment. JAMA 1993, 269:1953-1959. 10.1001/jama.269.15.1953, 8385230.
18. Firoz S, Carlson G. Characteristics and treatment outcome of older methadone-maintenance patients. Am J Geriatr Psychiatry 2004, 12:539-541.
19. Frank B. An overview of heroin trends in New York City: past, present and future. Mt Sinai J Med 2000, 67:340-346.
20. Lofwall MR, Brooner RK, Bigelow GE, Kindbom K, Strain EC. Characteristics of older opioid maintenance patients. J Subst Abuse Treat 2005, 28:265-272. 10.1016/j.jsat.2005.01.007, 15857727.
21. Rosen D. Factors associated with illegal drug use among older methadone clients. Gerontologist 2004, 44:543-547.
22. Goldberg RJ, Grabowski R. Methadone maintenance: its future in skilled nursing facilities. J Am Med Dir Assoc 2003, 4:98-100. 10.1016/S1525-8610(04)70283-2, 12807582.
23. Hser YI, Gelberg L, Hoffman V, Grella CE, McCarthy W, Anglin MD. Health conditions among aging narcotics addicts: medical examination results. J Behav Med 2004, 27:607-622. 10.1007/s10865-004-0005-x, 15669446.
24. Rajaratnam R, Sivesind D, Todman M, Roane D, Seewald R. The aging methadone maintenance patient: treatment adjustment, long-term success, and quality of life. J Opioid Manag 2009, 5:27-37.
25. Rosen D, Smith ML, Reynolds C. The prevalence of mental and physical health disorders among older methadone patients. Am J Geriatr Psychiatry 2008, 16:488-497. 10.1097/JGP.0b013e31816ff35a, 18515693.
26. Arndt S, Clayton R, Schultz SK. Trends in substance abuse treatment 1998-2008: increasing older adult first-time admissions for illicit drugs. Am J Geriatr Psychiatry
27. Addiction Treatment Forum Current comments - the further " graying of methadone". Addiction Treatment Forum 2003, 12:4-5. Addiction Treatment Forum.
28. Petitjean S. Methadone maintenance treatment in general practice or in specialized centers: profile and outcomes of patients in the Swiss canton of Basle 2010, Lengerich: Pabst Science Publishers.
29. Swiss Federal Office of Public Health Nationale Methadonstatistik [National statistics of methadone substitution treatment]. Swiss Federal Office of Public Health., http://www.bag.admin.ch/themen/drogen/00042/00632/03383/index.html?lang=fr
30. Swiss Society of Addiction Medicine (SSAM) Clinical recommendations for substitution-assisted treatment in opioid dependence. Swiss Society of Addiction Medicine (SSAM)., http://www.ssam.ch/SSAM/de/Substitutionsempfehlungen
31. Nordt C, Landolt K, Stohler R. Estimating incidence trends in regular heroin use in 26 regions of Switzerland using methadone treatment data. Subst Abuse Treat Prev Policy 2009, 4:14. 10.1186/1747-597X-4-14, 2708143, 19519920.
32. Maag V. Estimated trends in the prevalence of heroin addiction in Switzerland. A multiple-indicator approach. Eur Addict Res 2003, 9:176-181. 10.1159/000070984, 12970586.
33. Dickinson GL, Rostami-Hodjegan A, Lagundoye O, Seivewright N, Pratt P, Lennard MS. A six-year evaluation of methadone prescribing practices at a substance misuse treatment centre in the UK. J Clin Pharm Ther 2006, 31:477-484. 10.1111/j.1365-2710.2006.00767.x, 16958826.
34. Peles E, Schreiber S, Adelson M. Factors predicting retention in treatment: 10-year experience of a methadone maintenance treatment (MMT) clinic in Israel. Drug Alcohol Depend 2006, 82:211-217. 10.1016/j.drugalcdep.2005.09.004, 16219428.
35. Villafranca SW, McKellar JD, Trafton JA, Humphreys K. Predictors of retention in methadone programs: A signal detection analysis. Drug Alcohol Depend 2006, 83:218-224. 10.1016/j.drugalcdep.2005.11.020, 16384657.
36. Anderson JF, Warren LD. Client retention in the British Columbia Methadone Program, 1996-1999. Can J Public Health 2004, 95:104-109.
37. D'Ippoliti D, Davoli M, Perucci CA, Pasqualini F, Bargagli AM. Retention in treatment of heroin users in Italy: the role of treatment type and of methadone maintenance dosage. Drug Alcohol Depend 1998, 52:167-171. 10.1016/S0376-8716(98)00091-X, 9800146.
38. Joe GW, Simpson DD, Broome KM. Retention and patient engagement models for different treatment modalities in DATOS. Drug Alcohol Depend 1999, 57:113-125. 10.1016/S0376-8716(99)00088-5, 10617096.
39. Stohler R, Nordt C, Falcato L, Dürsteler-MacFarland K, Rössler W. Effektive Methadonbehandlungen: Vergleich der Behandlungsdauer in spezialisierten Institutionen und Privatpraxen [Is methadone maintenance provided by private practitioners effective?]. Soz Praventivmed 2004, 49:276-280.
40. Compton WM, Thomas YF, Conway KP, Colliver JD. Developments in the epidemiology of drug use and drug use disorders. Am J Psychiatry 2005, 162:1494-1502. 10.1176/appi.ajp.162.8.1494, 16055770.
41. Marshall BD, Fairbairn N, Li K, Wood E, Kerr T. Physical violence among a prospective cohort of injection drug users: a gender-focused approach. Drug Alcohol Depend 2008, 97:237-246. 10.1016/j.drugalcdep.2008.03.028, 2570226, 18487025.
42. Simmons LA, Havens JR, Whiting JB, Holz JL, Bada H. Illicit drug use among women with children in the United States: 2002-2003. Ann Epidemiol 2009, 19:187-193. 10.1016/j.annepidem.2008.12.007, 2680130, 19217001.
43. Balthasar H, Huissoud T, Zobel F, Arnaud S, Samitca S, Jeannin A, Schnoz D, Gervasoni JP, Dubois-Arber F. Entwicklung des Konsums und des Risikoverhaltens bezüglich HIV- und HCV-Übertragung bei Drogen injizierenden Personen in der Schweiz, 1993-2006 [Development of use and risk behaviour concerning transmission of HIV and HCV in drug-injecting persons in Switzerland, 1993-2006]. Bulletin - BAG 2007, 45:804-809.
44. UNODC World Drug Report 2004, Vienna; 2004, UNODC.
45. Maag V. Kokain - die neue Volksdroge? Nationale und internationale Trends [Cocaine--the new "people's drug"? National and international trends]. Abhängigkeiten 2006, 6:13-22.
46. Reece AS. Evidence of accelerated ageing in clinical drug addiction from immune, hepatic and metabolic biomarkers. Immunity & Ageing 2007, 4.
47. Fareed A, Casarella J, Amar R, Vayalapalli S, Drexler K. Benefits of retention in methadone maintenance and chronic medical conditions as risk factors for premature death among older heroin addicts. J Psychiatr Pract 2009, 15:227-234. 10.1097/01.pra.0000351884.83377.e2, 19461397.
48. Beynon C, McVeigh J, Hurst A, Marr A. Older and sicker: Changing mortality of drug users in treatment in the North West of England. Int J Drug Policy 2010, 21:429-431. 10.1016/j.drugpo.2010.01.012, 20172707.
49. Conner KO, Rosen D. "You're nothing but a junkie": The multiple experiences of stigma in an aging methadone maintenance population. Journal of Social Work Practice in the Addictions 2008, 8:244-264.
50. Anderson TL, Levy JA. Marginality among older injectors in today's illicit drug culture: assessing the impact of ageing. Addiction 2003, 98:761-770. 10.1046/j.1360-0443.2003.00388.x, 12780364.
51. Satre DD, Mertens J, Arean PA, Weisner C. Contrasting outcomes of older versus middle-aged and younger adult chemical dependency patients in a managed care program. J Stud Alcohol 2003, 64:520-530.
52. Rosen D, Morse JQ, Reynolds CF. Adapting problem-solving therapy for depressed older adults in methadone maintenance treatment. J Subst Abuse Treat 2011, 40:132-141. 10.1016/j.jsat.2010.09.003, 21036509.
53. Burns L, Randall D, Hall WD, Law M, Butler T, Bell J, Degenhardt L. Opioid agonist pharmacotherapy in New South Wales from 1985 to 2006: patient characteristics and patterns and predictors of treatment retention. Addiction 2009, 104:1363-1372. 10.1111/j.1360-0443.2009.02633.x, 19549053.
54. Adinoff B. Divided doses for methadone maintenance. Am J Psychiatry 2008, 165:303-305. 10.1176/appi.ajp.2007.07121944, 18316426.
55. Kim TW, Alford DP, Malabanan A, Holick MF, Samet JH. Low bone density in patients receiving methadone maintenance treatment. Drug Alcohol Depend 2006, 85:258-262. 10.1016/j.drugalcdep.2006.05.027, 16860495.
56. Abrams R, Alexopoulos G. Geriatric addictions. Clinical Textbook of Addictive Disorders 1998, 374-396. New York: Guilford, Frances R, Miller S, 2.
57. Dursteler-MacFarland KM, Stohler R, Moldovanyi A, Rey S, Basdekis R, Gschwend P, Eschmann S, Rehm J. Complaints of heroin-maintained patients: A survey of symptoms ascribed to diacetylmorphine. Drug Alcohol Depend 2006, 81:231-239. 10.1016/j.drugalcdep.2005.07.004, 16135401.
58. Bomsien S, Skopp G. An in vitro approach to potential methadone metabolic-inhibition interactions. Eur J Clin Pharmacol 2007, 63:821-827. 10.1007/s00228-007-0327-z, 17598095.
59. Eap CB, Déglon J-J, Baumann P. Pharmacokinetics and pharmacogenetics of methadone: clinical relevance. Heroin Add & Rel Clin Probl 1999, 1:19-34.
60. Garrido MJ, Troconiz IF. Methadone: a review of its pharmacokinetic/pharmacodynamic properties. J Pharmacol Toxicol Methods 1999, 42:61-66. 10.1016/S1056-8719(00)00043-5, 10924887.
61. Nicak A, Kohut A. Development of tolerance to morphine and pethidine in rats in dependence on age. Act Nerv Super (Praha) 1978, 20:231-235.
62. Buntin-Mushock C, Phillip L, Moriyama K, Palmer PP. Age-dependent opioid escalation in chronic pain patients. Anesth Analg 2005, 100:1740-1745. 10.1213/01.ANE.0000152191.29311.9B, 15920207.
63. Ryder N, Cullen W, Barry J, Bury G, Keenan E, Smyth BP. Prevalence of problem alcohol use among patients attending primary care for methadone treatment. BMC Fam Pract 2009, 10:42. 10.1186/1471-2296-10-42, 2702277, 19519882.
64. White JM, Irvine RJ. Mechanisms of fatal opioid overdose. Addiction 1999, 94:961-972. 10.1046/j.1360-0443.1999.9479612.x, 10707430.
65. Johnson TM, Cohen HW, Howard AA, Santoro N, Floris-Moore M, Arnsten JH, Hartel DM, Schoenbaum EE. Attribution of menopause symptoms in human immunodeficiency virus-infected or at-risk drug-using women. Menopause 2008, 15:551-557. 10.1097/gme.0b013e31815879df, 18188138.
66. Sherman J. Women on methadone. Aust Fam Physician 2006, 35:839. author reply 839.
67. Tuchman E. Exploring the prevalence of menopause symptoms in midlife women in methadone maintenance treatment. Soc Work Health Care 2007, 45:43-62.
68. Winick C. Maturing out of narcotic addiction. United Nations Bulletin on Narcotics 1962, 14:1-7.
69. Haastrup S, Jepsen PW. Eleven year follow-up of 300 young opioid addicts. Acta Psychiatr Scand 1988, 77:22-26. 10.1111/j.1600-0447.1988.tb05071.x, 3348092.
70. Weschules DJ, Bain KT, Richeimer S. Actual and potential drug interactions associated with methadone. Pain Med 2008, 9:315-344. 10.1111/j.1526-4637.2006.00289.x, 18386306.
71. Pollack HA, D'Aunno T. Dosage patterns in methadone treatment: results from a national survey, 1988-2005. Health Serv Res 2008, 43:2143-2163. 10.1111/j.1475-6773.2008.00870.x, 2613988, 18522665.
72. Strang J, Manning V, Mayet S, Ridge G, Best D, Sheridan J. Does prescribing for opiate addiction change after national guidelines? Methadone and buprenorphine prescribing to opiate addicts by general practitioners and hospital doctors in England, 1995-2005. Addiction 2007, 102:761-770. 10.1111/j.1360-0443.2007.01762.x, 17506153.